Xiang Zhisheng, Huang Yongying, Ma Jingyu, Lin Yongtian, Wen Yeying, Zhou Yan, Liu Jingfeng
Department of Epidemiology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No.420 Fuma Road, Fuzhou, 350014, China.
Department of Hepatopancreatobiliary Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No.420 Fuma Road, Fuzhou, 350014, China.
Arch Public Health. 2024 Dec 4;82(1):233. doi: 10.1186/s13690-024-01462-7.
Liver cancer is a common malignant tumor of the digestive system. We aimed to estimate the trend in the burden of liver cancer in Fujian Province, China, during 2011-2020.
The population-based cancer data was collected from the cancer registry in Fujian Province during 2011-2020. Segi's world standard population was used to calculate the age-standardized incidence rates and age-standardized mortality rates. The temporal trend of liver cancer was displayed by annual percentage change and average annual percentage change (AAPC). Relative survival of liver cancer was calculated as the ratio of observed survival to expected survival. The age-standardized relative survival was calculated according to the International Cancer Survival Standards 1.
There were 14,725 patients diagnosed with liver cancer and 12,698 patients died between 2011 and 2020. For males, there was a downward trend in incidence and mortality (AAPC: -3.86%, -3.44%). Similarly, the downward trend was also shown in females (AAPC: -3.96%, -2.79%). The highest age-specific incidence and mortality were in the 75-79 age group (146.59/100,000 and 137.99/100,000, respectively), and there was no downward trend in this group during the period. The overall age-standardized 5-year relative survival was 10.77% in 2011-2015 and 14.54% in 2016-2020. During the study period, the percentage improvement of survival was higher in males than in females (34.75% and 25.33%). The percentage improvement of survival in urban was higher than that in rural (38.64% and 28.75%). Except for the age group over 75, the survival of patients in other age groups all has improved.
Liver cancer remains a serious public health problem in Fujian Province, China, which needs to be solved, especially in some high-risk groups such as the elderly, high-risk males, and rural populations. Early detection and treatment is the key to the prevention and treatment of liver cancer.
肝癌是消化系统常见的恶性肿瘤。我们旨在评估2011 - 2020年中国福建省肝癌负担的趋势。
收集福建省2011 - 2020年癌症登记处基于人群的癌症数据。采用Segi世界标准人口计算年龄标准化发病率和年龄标准化死亡率。通过年度百分比变化和平均年度百分比变化（AAPC）展示肝癌的时间趋势。肝癌的相对生存率计算为观察生存率与预期生存率之比。年龄标准化相对生存率根据国际癌症生存标准1进行计算。
2011年至2020年期间，有14725例患者被诊断为肝癌，12698例患者死亡。男性的发病率和死亡率呈下降趋势（AAPC：-3.86%，-3.44%）。同样，女性也呈现下降趋势（AAPC：-3.96%，-2.79%）。年龄别发病率和死亡率最高的是75 - 79岁年龄组（分别为146.59/10万和137.99/10万），该组在此期间没有下降趋势。2011 - 2015年总体年龄标准化5年相对生存率为10.77%，2016 - 2020年为14.54%。在研究期间，男性生存率的提高百分比高于女性（34.75%和25.33%）。城市地区生存率的提高百分比高于农村地区（38.64%和28.75%）。除75岁以上年龄组外，其他年龄组患者的生存率均有所提高。
肝癌在中国福建省仍然是一个严重的公共卫生问题，需要解决，特别是在一些高危人群中，如老年人、高危男性和农村人口。早期发现和治疗是肝癌防治的关键。
